Abstract

Macrovascular disease is tightly associated with obesity-induced metabolic syndrome. Sitagliptin (SIT), an orally stable selective inhibitor of Dipeptidyl peptidase-4 (DPP-4), has protective effects on endothelium. However, the mechanisms enabling SIT to exhibit resistance to diet-induced obesity (DIO) related with reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress in the aorta and endothelial cells have not been reported yet. Therefore, the present study was conducted to determine if SIT exerts protective role in the thoracic aortas isolated from the high-fat diet (HFD)-treated rats and palmitate (PA)-treated endothelial cells by alleviating ROS and ER stress. Male Sprague Dawley rats were randomly divided into standard chow diet (SCD), HFD and HFD plus sitagliptin administration (HFD + SIT) groups. The rats of latter two groups were given HFD fodder for 12 weeks, then the HFD + SIT rats were treated with SIT (10 mg/kg/d) by intragastric administration for another 8 weeks. The body mass, vascular tension, serum oxidative stress indices and inflammatory parameters, pathological changes, protein expression of endothelial nitric oxide synthase (eNOS), the genes associated with ER stress and apoptosis in the thoracic aorta were measured. Furthermore, cell proliferation, ROS and the protein expression associated with ER stress (especially CHOP) and apoptosis were assessed in human umbilical vein endothelial cells (HUVECs) incubated with SIT and PA. Compared to the SCD rats, the HFD rats had higher serum lipid levels, decreased vascular tension, increased inflammation, oxidative and ER stress, and apoptosis of endothelial cells. PA promoted ROS generation, ER stress and apoptosis, inhibited cell proliferation in HUVECs. SIT treatment obviously ameliorated apoptosis via alleviating ROS and ER stress in the thoracic aortas isolated from HFD-fed rats and PA-treated HUVECs. The results suggest that SIT improved endothelial function via promoting cell proliferation and alleviating ROS-ER stress-CHOP pathway both in vivo and in vitro.

Highlights

  • Metabolic syndrome (MS), a cluster of metabolic abnormalities associated with insulin resistance and abdominal obesity, is related to increased risks of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) (Eva et al, 2011)

  • Serum TG, total cholesterol (TC), and low-density lipoprotein-cholesterol (LDL-C) levels were remarkably increased in the high-fat diet (HFD) group, and the high-density lipoprotein-cholesterol (HDL-C) levels were significantly decreased in the HFD group

  • We reported for the first time that SIT, as the first approved Dipeptidyl peptidase-4 (DPP4) inhibitor by the FDA to treat T2DM and MS, attenuated HFD/PA-induced Endothelial dysfunction (ED) and endothelial injuries in the thoracic aorta and human umbilical vein endothelial cells (HUVECs)

Read more

Summary

Introduction

Metabolic syndrome (MS), a cluster of metabolic abnormalities associated with insulin resistance and abdominal obesity, is related to increased risks of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) (Eva et al, 2011). High-fat diet (HFD)-induced obesity significantly increases the risk for MS. Macrovascular disease is one of the most common determiners of morbidity and mortality in obesityinduced MS (Koumaras et al, 2013). Endothelial dysfunction (ED), characterized by impaired nitric oxide (NO) release and increased endothelin-1 (ET-1) release, is fundamental in the early stage of CVD. Chronic exposure to high fat or high free saturated fatty acid drives inflammation, oxidative and endoplasmic reticulum (ER) stress in the endothelium (Lu et al, 2013). Endothelial cells (ECs) are distributed in the innermost layer of the endothelium, so damage to ECs is commonly thought to be the initial step of ED

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call